Roivant Sciences (ROIV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$34.93+1.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Roivant has a strong drug pipeline targeting big unmet needs. It beat earnings with EPS of $0.28 last quarter, well above estimates. The company has $4.3 billion in cash and announced a $1 billion share buyback. These show financial strength despite current losses.
Roivant is still loss-making with negative EPS expected next year. Analysts forecast revenue to drop about 60% next year. Ongoing litigation and no clear revenue guidance add risk. The turnaround may stall if losses continue.
The stock trades about 10% below our fair value near $40. Analysts expect a 60% revenue decline, which we view as too pessimistic. Our fair value aligns with the Street median, suggesting some upside if the turnaround progresses.
Breaks if: Cash falls below $4B or buyback program halted
Breaks if: EPS falls below -0.4 next quarter
Revenue decline exceeds 20% next fiscal year
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The company is currently loss-making but has shown strong recent financial performance and stable management, which supports the thesis.
The market appears to have a low expectations gap, indicating that it may not fully account for the company's recent improvements and the potential for future growth. The current valuation suggests that the stock is viewed as unjustified in terms of its performance relative to peers.
Management has successfully launched brepocitinib and is advancing clinical development for IMVT-1402, which are key priorities. The trajectory for net income and operating income has improved significantly, indicating a positive trend in fundamentals.
The long-term thesis hinges on the company's ability to maintain its momentum in the healthcare sector and manage risks related to potential earnings guidance cuts. Additionally, the performance of sector bellwethers could influence ROIV's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company beat earnings expectations recently. It also received FDA approval for LISRAYA in dermatomyositis. This approval speeds up the launch of brepocitinib. There are no current threats to the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Overall, ROIV's fundamentals are on track, but the investment outlook will depend on continued execution and sector performance. Not investment advice.